PEP-MT2 • RESEARCH USE ONLY

Melanotan II

Melanotan II is a synthetic melanocortin peptide that activates melanocortin receptors (primarily MC1R and MC4R). It stimulates melanin production in the skin and also influences appetite regulation, libido, and mood through central nervous system pathways. Unlike Melanotan I, MT-2 crosses the blood–brain barrier, which explains its broader systemic effects beyond pigmentation.

15 mg

Per Bottle
94 mcg per spray

>99%

Purity
Third-party verified

160

Sprays per bottle
Protocol & Dosing

is typically used in cycles, beginning with a low-dose loading phase to assess individual tolerance. Use commonly starts with one spray daily, with the option to increase to two sprays daily if well tolerated. After an initial 2–4 week loading period, users often transition to a maintenance phase of one to two sprays per week to maintain results. Cycles are commonly continued for 8–12 weeks, followed by a break before repeating.

Standard
2 sprays daily
Higher
2 sprays twice daily (only if well tolerated)
Key Benefits

Melanotan II supports increased melanin production, leading to enhanced skin pigmentation and improved tolerance to UV exposure. In addition to its tanning effects, it may support libido enhancement, mild appetite suppression, and mood elevation due to its action on central melanocortin receptors. These combined effects make Melanotan II a multifaceted peptide often used for aesthetic, metabolic, and wellness-oriented goals.

Guidance
  • Start low to assess tolerance
  • Begin with 1 spray daily for 5–7 days
  • Increase to 2 sprays daily only if no nausea, flushing, or headaches occur
  • If side effects appear, reduce the dose or pause use
  • Evening dosing may improve tolerability for some individuals
  • Maintain consistent dosing times and stay well hydrated
  • Intended for cyclical use
  • Loading phase: 2–4 weeks of daily dosing
  • Maintenance phase: 1–2 sprays per week to maintain results
  • Typical cycle length: 8–12 weeks
  • Cycle break: Take 4–8 weeks off before repeating
  • Avoid excessive UV exposure during early use
  • Monitor skin for changes in pigmentation or moles during use
PROPRIETARY DELIVERY TECHNOLOGY

Protixa ION System™

Nasal delivery is facilitated with the Protixa ION System — a proprietary liquid ion delivery platform engineered for enhanced bioavailability, deep tissue penetration, and improved compound stability without compromising safety. Unlike carriers that rely on encapsulation, it enables direct solubilization and optimized partitioning of actives including peptides and coenzymes — no liposomes, no lipid nanoparticles, no emulsifier-dependent payloads. Built from amino acids and endogenous molecules for biocompatibility; scalable across routes that include intranasal sprays.

Lipid disruption & cation exchange
Alkyl chains intercalate into the stratum corneum lipid matrix via hydrophobic interactions, reducing cohesion and increasing permeability. Cationic components displace native ions such as Ca²⁺ within lipid lamellae, weakening structural integrity so actives pass through more efficiently.
Dual-polarity solubilization
Hydrophilic and lipophilic character solubilizes and transports a broad range of actives directly — without emulsifiers or encapsulating carriers.
Keratin modulation & partitioning
Temporarily denatures keratin within corneocytes, opening transient micro-pathways for epithelial migration. Improves solubility and skin partitioning while maintaining proprietary differentiation for IP — inspired by systems like CAGE (choline–geranic acid ionic liquids).
Superior loading vs. lipid carriers
Solubilizes actives directly instead of inefficient encapsulation. In-house studies: lipid-based carriers penetrated only ~22 μm — insufficient for meaningful absorption — whereas the Protixa ION System reaches therapeutically relevant layers.
>57× vs. saline · <10 nm (DLS)
>57× barrier penetration vs. saline in an ex vivo epithelial model (Protixa third-party data). Minimum confirmed nanoparticle size under 10 nm — mucus-penetrating ionic clusters by dynamic light scattering.
Safety, stability & distribution
ISO 10993-5 CCK-8 assay: 80–100% viability at 24 h and 48 h. Four-month room-temperature stability: 101.1–101.9% HPLC recovery — no cold chain. In vivo oral mouse study: systemic distribution across five organs at 1 hour post-dose.

Compliance · Nasal peptides

cGMP manufacturing & cryopreservation

Manufactured through Pacific Manufacturing & Design LLC — GMP-certified under NSF/ANSI 455-2 and FDA-registered (Reg. No. 15492349536). Compliant with 21 CFR Parts 11, 111, and 117. Strict quality control, validated processes, and full traceability from raw material to final product.

NSF/ANSI 455-2FDA REGISTERED21 CFR PART 11121 CFR PART 117
Third-Party COA — Every Batch

Third-party COA for every batch, ensuring consistent quality and purity. Verified through LCMS and endotoxin testing, with full traceability from raw material to final product.

LCMS CONFIRMED>99% PURITYENDOTOXIN TESTEDAXISPHARM COA